首页> 外文期刊>International Journal of Pharmaceutics >In-vitro and in-vivo evaluation of taste-masked cetirizine hydrochloride formulated in oral lyophilisates
【24h】

In-vitro and in-vivo evaluation of taste-masked cetirizine hydrochloride formulated in oral lyophilisates

机译:口服冻干物中配制的掩味西替利嗪盐酸盐的体外和体内评价

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The use of solid oral dosage forms is typically favored with regard to stability and ease of administration. The aim of this study was to investigate whether cyclodextrins (CD) or ion exchange resins (IER) could be used to taste-mask cetirizine HCl when formulated in a freeze-dried oral formulation. The oral lyophilisates were produced using the Zydis (R) technology that offer the opportunity to produce the dosage form directly in the aluminum laminate blister packs. This study confirmed that a pre-formed resinate of cetirizine HCl and various cyclodextrins can be successfully incorporated into the Zydis (R) oral lyophilisate. A chemically stable product with acceptable release profile was obtained in the case of cyclodextrin. This study has also demonstrated that the Insent (R) taste sensing system is a useful technique for predicting the taste-masking potential of Zydis (R) formulations. The electronic taste sensing system (e-tongue) data can be used to provide guidance on the selection of taste-masked formulations. Principal component analysis (PCA) of sensor data by plotting the PCA scores revealed the effects of used taste-masking techniques on the e-tongue sensors, indicating the successful taste improvement. The PCA plot of the taste sensor data revealed larger distances between the non-taste-masked sample and the CD-and IER-loaded samples, and the shift toward the drug-free formulations and excipient signals indicates a modification of the product taste. The human taste trial confirms the acceptability of the selected promising formulations. The taste evaluation results showed that an effectively taste-masked formulation has been achieved using beta-cyclodextrin and cherry/sucralose flavor system with over 80% of volunteers finding the tablet to be acceptable. (C) 2015 Elsevier B.V. All rights reserved.
机译:就稳定性和易于给药而言,固体口服剂型的使用通常是有利的。这项研究的目的是研究将环糊精(CD)或离子交换树脂(IER)配制成冷冻干燥的口服制剂时是否可用于掩盖西替利嗪HCl。口服冻干物是使用Zydis技术生产的,该技术提供了直接在铝层压板泡罩包装中生产剂型的机会。这项研究证实,预先形成的盐酸西替利嗪和各种环糊精的树脂酸酯可以成功地掺入口服冻干酸酯中。在环糊精的情况下,获得具有可接受的释放曲线的化学稳定的产物。这项研究还表明,Insent(R)味觉系统是预测Zydis(R)配方掩味潜力的有用技术。电子味觉系统(电子舌)数据可用于为掩味配方的选择提供指导。通过绘制PCA分数绘制传感器数据的主成分分析(PCA),揭示了使用过的掩味技术对电子舌头传感器的影响,表明成功地改善了口味。味道传感器数据的PCA图显示,未掩盖味道的样品与装有CD和IER的样品之间的距离更大,并且向无药物配方和赋形剂信号的转移表明产品味道得到了改变。人体口味试验证实了所选有希望的配方的可接受性。味道评估结果表明,使用β-环糊精和樱桃/三氯蔗糖风味系统已实现了有效的掩味配方,超过80%的志愿者认为该片剂可接受。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号